GSM gold starGSM Global
中文版 · Chinese

Canada's Competition Bureau Concludes Express Scripts Canada Investigation, Finding Insufficient Evidence of Abuse of Dominance While Issuing Guidance on Preferred Provider Networks

Monday, November 16, 2026 · World · GSM News

Canada's Competition Bureau on 16 November issued a position statement in Gatineau, Quebec, saying that on 8 September 2026 it discontinued its inquiry into whether Express Scripts Canada, one of Canada's largest pharmacy benefit managers, engaged in conduct contrary to the abuse of dominance provisions of the Competition Act.

The Bureau said the inquiry followed complaints received beginning in January 2024 about Express Scripts' service fees to retail pharmacies and its audit practices, and that it launched a civil inquiry in November 2024. The investigation focused on whether the company engaged in self-preferencing by using preferred provider networks to force or induce patients to use an Express Scripts owned or associated pharmacy rather than their pharmacy of choice, and on whether it squeezed the margins of rival pharmacies through service fees and audit practices. During the investigation, the Bureau gathered information from Express Scripts and other market participants, including pharmacies and insurers, and obtained a court order requiring the company to produce records, written information and oral testimony.

Based on the evidence gathered, the Bureau found insufficient evidence to conclude that Express Scripts abused a dominant position in either area. It said the company's mandatory or closed preferred provider networks are not widely used in Canada and its mail-order pharmacies account for only a small share of prescriptions, and the evidence did not indicate the networks were implemented for the purpose of excluding competitors or had the effect of harming competition substantially. On service fees and audits, the evidence did not establish an intent to exclude competitors or a substantial effect on competition, although pharmacies expressed concerns about costs and administrative burden.

The Bureau said it remains concerned about the potential harm to competition that can result from preferred provider networks, and issued guidance to help industry participants identify features that may raise competition concerns, including where parties have market power, are vertically integrated, limit which pharmacies can participate, require or strongly incentivize use of in-network pharmacies, or capture a large share of patients. It said that if new information comes to light suggesting a preferred provider network raises issues under the Competition Act, it will not hesitate to take appropriate enforcement action.

Published by GSM · USA (original Chinese edition)

Photo: Wikimedia Commons, File:5033 Hurontario St Shoppers Drug Mart Interior 2023.jpg — Author: Canmenwalker. Licensing: CC BY 4.0.

Latest in World